Literature DB >> 15793098

Accumulation and oriented transport of ampicillin in Caco-2 cells from its pivaloyloxymethylester prodrug, pivampicillin.

Hugues Chanteux1, Françoise Van Bambeke, Marie-Paule Mingeot-Leclercq, Paul M Tulkens.   

Abstract

Pivampicillin (PIVA), an acyloxymethylester of ampicillin, is thought to enhance the oral bioavailability of ampicillin because of its greater lipophilicity compared to that of ampicillin. The fate of PIVA in intestinal cells and the exact location of its conversion into ampicillin have, however, never been unambiguously established. Polarized Caco-2 cells have been used to examine the handling of PIVA and the release of ampicillin from PIVA by the intestinal epithelium. Experiments were limited to 3 h. Cells incubated with PIVA (apical pole) showed a fast accumulation of ampicillin and transport toward the basolateral medium, whereas PIVA itself was only poorly accumulated and transported. Cells incubated with free ampicillin accumulated and transported only minimal amounts of this drug. Release of ampicillin from cells incubated with PIVA was unaffected by PEPT1 and OCTN2 inhibitors but was sharply decreased after ATP depletion or addition of bis(4-nitrophenyl)-phosphate (BNPP; an esterase inhibitor). PIVA incubated with Caco-2 lysates released free ampicillin, and this release was inhibited by BNPP. Efflux studies showed that the ampicillin that accumulated in cells after incubation with PIVA was preferentially transported out of the cells through the basolateral pole. This efflux was decreased by multidrug resistance-associated protein (MRP) inhibitors (probenecid, MK-571) and by ATP depletion. A phthalimidomethylester of ampicillin that resists cellular esterases failed to cause any significant release (cell lysate) or transport (polarized Caco-2 cells) of ampicillin. These results show that when PIVA is given to Caco-2 cells from their apical pole, ampicillin is released intracellularly and that ampicillin is thereafter preferentially effluxed into the basolateral medium through an MRP-like transporter.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15793098      PMCID: PMC1068589          DOI: 10.1128/AAC.49.4.1279-1288.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  53 in total

1.  The role of an alpha-amino group on H+ -dependent transepithelial transport of cephalosporins in Caco-2 cells.

Authors:  S D Raeissi; J Li; I J Hidalgo
Journal:  J Pharm Pharmacol       Date:  1999-01       Impact factor: 3.765

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Mechanism of intestinal absorption of an orally active beta-lactam prodrug: uptake and transport of carindacillin in Caco-2 cells.

Authors:  Y H Li; K Ito; Y Tsuda; R Kohda; H Yamada; T Itoh
Journal:  J Pharmacol Exp Ther       Date:  1999-09       Impact factor: 4.030

4.  Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux.

Authors:  B Bretschneider; M Brandsch; R Neubert
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

5.  Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane.

Authors:  J König; D Rost; Y Cui; D Keppler
Journal:  Hepatology       Date:  1999-04       Impact factor: 17.425

6.  Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds.

Authors:  R Yumoto; T Murakami; Y Nakamoto; R Hasegawa; J Nagai; M Takano
Journal:  J Pharmacol Exp Ther       Date:  1999-04       Impact factor: 4.030

7.  Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.

Authors:  R Ohashi; I Tamai; H Yabuuchi; J I Nezu; A Oku; Y Sai; M Shimane; A Tsuji
Journal:  J Pharmacol Exp Ther       Date:  1999-11       Impact factor: 4.030

Review 8.  Strategies for absorption screening in drug discovery and development.

Authors:  H Bohets; P Annaert; G Mannens; L Van Beijsterveldt; K Anciaux; P Verboven; W Meuldermans; K Lavrijsen
Journal:  Curr Top Med Chem       Date:  2001-11       Impact factor: 3.295

9.  Transport and uptake of nateglinide in Caco-2 cells and its inhibitory effect on human monocarboxylate transporter MCT1.

Authors:  Atsuko Okamura; Akiko Emoto; Noriko Koyabu; Hisakazu Ohtani; Yasufumi Sawada
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

10.  Studies on functional sites of organic cation/carnitine transporter OCTN2 (SLC22A5) using a Ser467Cys mutant protein.

Authors:  Rikiya Ohashi; Ikumi Tamai; Akihiro Inano; Masaki Katsura; Yoshimichi Sai; Jun-ichi Nezu; Akira Tsuji
Journal:  J Pharmacol Exp Ther       Date:  2002-09       Impact factor: 4.030

View more
  1 in total

Review 1.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.